RNA vaccine developer Moderna (MRNA) is sinking 9% after Goldman Sachs downgraded the shares to Neutral from Buy. Why Goldman ...

Goldman Sachs analyst Salveen Richter downgraded Moderna (NASDAQ:MRNA) stock from Buy to Neutral, significantly reducing the price target to $51 from the previous $99. Trading at $44.94, the stock has ...

See the planned lavish compound, which comes with a car museum, a padel court, and a shooting range. It's America's most ...

Other potential buyers include the philanthropist Frank Mccourt ’s Project Liberty, which is raising capital to make a bid for TikTok in order to “rearchitect the platform” and protect user data.

In a report released today, Tyler Van Buren from TD Cowen maintained a Hold rating on Moderna (MRNA – Research Report), with a price target of ...

Goldman Sachs downgraded Moderna (MRNA) to Neutral from Buy with a price target of $51, down from $99. The recent product revenue guidance ...

USA News Group News Commentary ? As the new administration starts to make its mark in the United States, President Trump recently announced a $500 billion AI infrastructure investment in the country, ...